Elucid Appoints Dr. Robert Pelberg as New Senior Vice President of Medical Affairs

Business Wire

9 hours ago

BOSTON--(BUSINESS WIRE)-- Elucid, an AI medical technology company focused on providing physicians with a more precise view of atherosclerosis to drive patient-specific therapeutic decisions, has named Dr. Robert 'Bob' Pelberg as its new senior vice president of medical affairs. A highly accomplished cardiologist and nationally recognized expert in cardiovascular computed tomography angiography (CCTA), Dr. Pelberg brings to Elucid decades of clinical experience and a deep understanding of advanced imaging technologies and clinical research. In his new role, he will help shape and execute the company's clinical and research strategies and will lead the company's clinical operations quality efforts, ensuring compliance to the highest clinical quality and regulatory standards.
'Dr. Pelberg's appointment marks a critical step in Elucid's mission to deliver clinically valuable and scientifically rigorous tools to physicians."
Share
Dr. Pelberg's hiring comes at a pivotal moment for Elucid, as it accelerates both its clinical research strategy and commercial growth of its flagship product PlaqueIQ TM image analysis software. PlaqueIQ is the first and only FDA-cleared, non-invasive plaque analysis based on objective histology rather than subjective CCTA visual estimates. PlaqueIQ quantifies and classifies plaque morphology based on ground-truth histology, the gold standard for characterization of plaques.​ The software is designed to help physicians prioritize and personalize treatment based on actual disease, rather than population-based risk.
'Dr. Pelberg's appointment marks a critical step in Elucid's mission to deliver clinically valuable and scientifically rigorous tools to physicians. He will play a key role in expanding awareness of the company's software and key features within the medical community—engaging with clinicians, guiding study design, and articulating the clinical value of Elucid's histology-based technology in improving cardiovascular care, with our plaque analysis software today and our FFR-CT product in the near future,' said Kelly Huang, CEO of Elucid. 'Together, we are committed to helping align product development with real-world clinical needs, ultimately enhancing the impact of Elucid's work in transforming diagnostics for coronary artery disease.'
Dr. Pelberg is board certified in cardiovascular diseases, cardiac CT angiography, nuclear cardiology and echocardiography. He is a fellow of the American College of Cardiology, the American Heart Association, the American Society of Echocardiography, the American Society of Nuclear Cardiology and the Society of Cardiovascular Computed Tomography. He is also the author and co-author of numerous books as well as clinical publications in the field of cardiac CT. With extensive leadership experience directing cardiovascular service line clinical operations, he most recently served as a clinical cardiologist and advanced cardiac imager at The Christ Hospital Heart and Vascular Institute.
'As physicians, we know the importance of having a clear understanding of each patient's coronary plaque and how that impacts their risk of future cardiac events, including heart attack and stroke, as well as how to care for each individual based on their own plaque assessment. I share Elucid's vision of a future where physicians will be able to incorporate patient specific plaque characteristics to create personalized care pathways in coronary artery disease that can ultimately help reverse the prevalence of heart attack and stroke,' said Dr. Pelberg. 'I look forward to contributing to the company's mission and helping deliver on that goal.'
About Elucid
Elucid is a Boston-based AI medical technology company dedicated to developing technology designed to provide physicians with a more precise view of atherosclerosis (coronary plaque buildup), the root cause of cardiovascular disease. The company's PlaqueIQ TM image analysis software is designed to help physicians prioritize and personalize treatment based on actual disease, rather than population-based risk of disease. PlaqueIQ includes the only FDA-cleared computed tomography angiography (CTA) algorithm that objectively quantifies plaque morphology validated against ground truth histology, the gold standard for characterization of plaque, as indicated by renowned pathologists. PlaqueIQ equips physicians with critical information regarding the type and amount of plaque in arteries that can lead to heart attack and stroke. Elucid is also pursuing an indication for FFR CT, derived from its plaque algorithm, to help identify coronary blockages and the extent of ischemia non-invasively. For more information, visit elucid.com.